Synthesis and antiviral activity of a novel class of HIV-1 protease inhibitors containing a heterocyclic P1′-P2′ amide bond isostere
Authors:
- Scott K. ThompsonSTScott K. Thompson
- Alecia M. EppleyAEAlecia M. Eppley
- James S. FrazeeJFJames S. Frazee
- Michael G. DarcyMDMichael G. Darcy
- Robert T. LumRLRobert T. Lum
- Thaddeus A. TomaszekTTThaddeus A. Tomaszek
- Lucinda A. IvanoffLILucinda A. Ivanoff
- Jane F. MorrisJMJane F. Morris
- Edmund J. SternbergESEdmund J. Sternberg
- Dennis M. LambertDLDennis M. Lambert
- Annabellee V. FernandezAFAnnabellee V. Fernandez
- Stephen R. PettewaySPStephen R. Petteway
- 1 October 1994
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 4 (20) , 2441-2446
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease InhibitorsScience, 1994
- Inhibitors of Aspartyl ProteinasesMedicinal Research Reviews, 1993
- Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysisBiochemistry, 1993
- X-ray crystal structure of the HIV protease complex with L-700,417, an inhibitor with pseudo C2 symmetryJournal of the American Chemical Society, 1991
- Design, Activity, and 2.8 Å Crystal Structure of a C 2 Symmetric Inhibitor Complexed to HIV-1 ProteaseScience, 1990
- A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle MaturationScience, 1990
- Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analoguesNature, 1990
- AIDS in 1988Scientific American, 1988
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences of the United States of America, 1988
- HTLV-III gag Protein Is Processed in Yeast Cells by the Virus pol -ProteaseScience, 1986